Opko buys Israeli biopharma in $480M all-stock deal

Opko Health agreed to purchase Prolor Biotech, an Israel-based biopharmaceutical firm that develops longer-acting versions of approved therapeutic proteins, for around $480 million. "Prolor's drug-product candidates for growth hormone deficiency, hemophilia, obesity and diabetes, along with its broadly applicable technology platforms and efficient research and development center are highly valuable assets that will complement Opkos strategy," Opko Chairman and CEO Phillip Frost said.

View Full Article in:

Globes (Israel) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA